Johnson & Johnson ignores pressure to focus on drug production only

In the past decade, more and more shareholders have pushed pharmaceutical firms to focus solely on drug production, causing companies like Pfizer and Merck to sell their consumer goods businesses. However, Johnson & Johnson continues to ignore this trend.

Advertisement

The healthcare conglomerate, based in New Brunswick, N.J., recently acquired hair care company Vogue International for $3.3 billion, according to The New York Times.

While Johnson & Johnson’s drug division thrives, the consumer goods section produces lower margins than rivals and the medical device division remains stagnant since 2010.

Last year, Artisan Partners tried to pressure Johnson & Johnson to split. As Artisan owned well under 1 percent of its stock, the shareholders lacked the power to sway the conglomerate and its $312 billion market value.

More articles on supply chain:

FDA issues final guidance over post-market surveillance for medical devices
These drug, device companies are offering money-back guarantees to hospitals, payers
Medical device sales drive Medtronic’s $1.1B net income in Q4

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.